Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amid Controversy, Duchenne Muscular Dystrophy Drug Is Approved By FDA


Muscular Dystrophy

Earlier this year, FDA medical staffers raised a number of concerns about the drug, including the fact that it was only tested in a small 12-patient clinical trial.

Tweetables from this article:

Tweet: #FDA staffers raised concerns about #Duchennemusculardystrophy drug including size of 12-patient #clinicaltrial http://ctt.ec/QC7aO+FDA staffers raised concerns about Duchenne muscular dystrophy drug including size of 12-patient clinical trial.

Share this!

September 20, 2016 | by Sarah Hand, M.Sc.

A new drug developed to treat the rare disease Duchenne muscular dystrophy, has been approved by the US Food and Drug Administration (FDA). Benefitting from an accelerated approval, Sarepta Therapeutics’ Exondys 51 is the first drug to become available to patients with the disease.

As suggested by its name, Exondys 51 was developed for Duchenne muscular dystrophy patients with a mutation in the dystrophin gene on exon 51. The drug can encourage cellular machinery to skip exon 51, thereby producing a more functional protein.* This mutation is found in approximately 13 percent of the Duchenne muscular dystrophy patient population.

“Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “In rare diseases, new drug development is especially challenging due to the small numbers of people affected by each disease and the lack of medical understanding of many disorders. Accelerated approval makes this drug available to patients based on initial data, but we eagerly await learning more about the efficacy of this drug through a confirmatory clinical trial that the company must conduct after approval.”

Potential approval of the drug was debated for months, with some concerned that the drugmaker lacked evidence that Exondys 51 had a significant impact on patients. Earlier this year, FDA medical staffers raised a number of concerns about the drug, including the fact that it was only tested in a small 12-patient clinical trial.

While the FDA decided to approve the drug in spite of these issues, they are requiring Sarepta to conduct an additional randomized controlled trial to reconfirm the patient benefits of the drug over a two-year period. If that trial fails to show a significant improvement in motor functions in Duchenne muscular dystrophy patients, the FDA could rescind Exondys 51’s approval.

Duchenne muscular dystrophy is a rare genetic disease caused by a lack of the protein responsible for maintaining muscle cell integrity, known as dystrophin. This deficiency results in muscle deterioration and weakness which first begins to manifest between three and five years of age, with progressive worsening over time.

*Editor's Note: Sentence was rewritten to clarify action of Exondys 51.

Keywords: FDA, Muscular Dystrophy, Rare Disease


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.